No Data
RxSight, Inc.'s (NASDAQ:RXST) Stock Retreats 25% But Revenues Haven't Escaped The Attention Of Investors
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
RxSight Down Over 13%, on Pace for Largest Percent Decrease Since June 2022 -- Data Talk
Stifel Downgrades RxSight(RXST.US) to Hold Rating, Cuts Target Price to $40
Hold Rating Issued Amidst Rising Competition and Market Uncertainty for RxSight
RxSight Cut to Hold at Stifel on Competition Concerns